相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis
Maya Balakrishnan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
Zobair M. Younossi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Research in brief
Holly Baker
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison et al.
HEPATOLOGY COMMUNICATIONS (2021)
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the US
Zobair M. Younossi et al.
DIABETES CARE (2020)
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
Fernando Bril et al.
JOURNAL OF HEPATOLOGY (2020)
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Kenneth Cusi
DIABETES CARE (2020)
Therapeutic landscape for NAFLD in 2020
Brent A. Neuschwander-Tetri
GASTROENTEROLOGY (2020)
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Gordon Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo et al.
HEPATOLOGY (2019)
AMP-activated protein kinase: the current landscape for drug development
Gregory R. Steinberg et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al.
JHEP REPORTS (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
AMPK: guardian of metabolism and mitochondrial homeostasis
Sebastien Herzig et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Promise and challenges for direct small molecule AMPK activators
Severine Olivier et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Matteo Tacelli et al.
PHARMACEUTICALS (2018)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
Treatment of nonalcoholic fatty liver disease: role of AMPK
Brennan K. Smith et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Current efforts and trends in the treatment of NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2015)
Liver Fat Quantification Using a Multi-Step Adaptive Fitting Approach with Multi-Echo GRE Imaging
Xiaodong Zhong et al.
MAGNETIC RESONANCE IN MEDICINE (2014)
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Anila K. Madiraju et al.
NATURE (2014)
Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle
I. Chopra et al.
DIABETOLOGIA (2012)
Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans
Marie-Soleil Gauthier et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
AMPK inhibition in health and disease
Benoit Viollet et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Visceral fat: A key mediator of steatohepatitis in metabolic liver disease
David van der Poorten et al.
HEPATOLOGY (2008)
Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats
EW Kraegen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
JD Browning et al.
HEPATOLOGY (2004)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
分享论文
